نتایج جستجو برای: valsartan

تعداد نتایج: 2332  

Journal: :The New England journal of medicine 2010
John J McMurray Rury R Holman Steven M Haffner M Angelyn Bethel Björn Holzhauer Tsushung A Hua Yuri Belenkov Mitradev Boolell John B Buse Brendan M Buckley Antonio R Chacra Fu-Tien Chiang Bernard Charbonnel Chun-Chung Chow Melanie J Davies Prakash Deedwania Peter Diem Daniel Einhorn Vivian Fonseca Gregory R Fulcher Zbigniew Gaciong Sonia Gaztambide Thomas Giles Edward Horton Hasan Ilkova Trond Jenssen Steven E Kahn Henry Krum Markku Laakso Lawrence A Leiter Naomi S Levitt Viacheslav Mareev Felipe Martinez Chantal Masson Theodore Mazzone Eduardo Meaney Richard Nesto Changyu Pan Rudolf Prager Sotirios A Raptis Guy E H M Rutten Herbert Sandstroem Frank Schaper Andre Scheen Ole Schmitz Isaac Sinay Vladimir Soska Steen Stender Gyula Tamás Gianni Tognoni Jaako Tuomilehto Alberto S Villamil Juraj Vozár Robert M Califf

BACKGROUND It is not known whether drugs that block the renin-angiotensin system reduce the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance. METHODS In this double-blind, randomized clinical trial with a 2-by-2 factorial design, we assigned 9306 patients with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors...

Journal: :Hypertension 2006
Stevo Julius Michael A Weber Sverre E Kjeldsen Gordon T McInnes Alberto Zanchetti Hans R Brunner John Laragh M Anthony Schork Tsushung A Hua John Amerena Ivan Balazovjech Graham Cassel Bela Herczeg Nevres Koylan Dieter Magometschnigg Silja Majahalme Felipe Martinez Willie Oigman Ricardo Seabra Gomes Jun-ren Zhu

In the main Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) report, we investigated outcomes in 15 245 high-risk hypertensive subjects treated with valsartan- or amlodipine-based regimens. In this report, we analyzed outcomes in 7080 patients (46.4%) who, at the end of the initial drug adjustment period (6 months), remained on monotherapy. Baseline characteristics were similar in th...

2009
J Schrader A Salvetti C Calvo E Akpinar L Keeling M Weisskopf P Brunel

AIMS To demonstrate the benefit of the combination amlodipine/valsartan 5/160 mg over amlodipine 10 mg, in producing a lower incidence of peripheral oedema for a comparable mean sitting systolic blood pressure (MSSBP) reduction. METHODS After a 4-week amlodipine 5 mg run-in phase, inadequately controlled hypertension patients (aged > or = 55 years, MSSBP > or = 130 and < or = 160 mmHg) were r...

2015
Dion H. Zappe Nora Crikelair Albert Kandra Paolo Palatini

OBJECTIVE Studies suggest that bedtime dosing of an angiotensin-converting enzyme (ACE)-inhibitor or angiotensin receptor blocker shows a more sustained and consistent 24-h antihypertensive profile, including greater night-time blood pressure (BP) reduction. We compared the antihypertensive effects of morning (a.m.) and evening (p.m.) dosing of valsartan on 24-h BP. METHODS This 26-week, mult...

Journal: : 2022

Heart failure (HF) is the cause of impaired exercise capacity due to insufficient peripheral blood flow. Development natriuretic peptide (NP) through inhibition neprilysin enzyme therapeutic target in HF. Treatment with sacubitril/valsartan has been shown significantly reduce mortality and hospitalization rehospitalization rates for HF compared enalapril. Sacubitril/valsartan may provide signif...

1999
Lawrence Baruch Ira S. Cohen Jay N. Cohn

Background—ACE inhibitors may not adequately suppress deleterious levels of angiotensin II in patients with heart failure. An angiotensin receptor blocker added to an ACE inhibitor may exert additional beneficial effects. Methods and Results—Eighty-three symptomatic stable patients with chronic heart failure receiving long-term ACE inhibitor therapy were randomly assigned to double-blind treatm...

Journal: :American heart journal 2016
Ronnie Ramadan Saurabh S Dhawan José Nilo G Binongo Ayman Alkhoder Dean P Jones John N Oshinski Arshed A Quyyumi

BACKGROUND Progression of atherosclerosis is associated with a greater risk for adverse outcomes. Angiotensin II plays a key role in the pathogenesis and progression of atherosclerosis. We aimed to investigate the effects of angiotensin II type-1 receptor blockade with Valsartan on carotid wall atherosclerosis, with the hypothesis that Valsartan will reduce progression of atherosclerosis. MET...

2013
K.A. Al Balushi J.Q. Habib I. Al-Zakwani

OBJECTIVE To compare blood pressure (BP) control in patients receiving irbesartan/hydrochlorothiazide (HCTZ) and valsartan/HCTZ at a tertiary care university hospital in Oman. SUBJECTS AND METHODS This was a retrospective observational study, where 232 patients' medical records were reviewed during a 3-month period, July to September 2010, at Sultan Qaboos University Hospital in Oman. BP read...

Journal: :Hypertension 2010
Jennifer L Wilkinson-Berka Ronen Heine Genevieve Tan Mark E Cooper Kate M Hatzopoulos Erica L Fletcher Katrina J Binger Duncan J Campbell Antonia G Miller

The (pro)renin receptor [(P)RR] is implicated in organ pathology. We examined the cellular location of the (P)RR and whether a putative (P)RR antagonist, RILLKKMPSV, corresponding to the handle region of the prorenin prosegment (handle region peptide [HRP]) influences angiogenesis, inflammation, and neuronal and glial function in rat retina. The (P)RR was localized to retinal vessels, endotheli...

ارجمند عباسی, یاسمن, عیدی, اکرم, محمدی, محمد تقی,

Background and Objective: The use of AT1 and ACE inhibitors, as antihypertensive drugs, improves memory function in the elderly people with hypertension and vulnerable to Alzheimer’s disease (AD). Therefore, the aim of this study was to evaluate effects of oral administration of Captopril and Valsartan on memory function and expression of brain-derived neurotrophic factor (BDNF) in experimental...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید